We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.

Structure Therapeutics (GPCR) rose 1.5% after a report suggested that the obesity drug maker could be a top takeover target ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S. Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $103.82 / share. This is an increase of 10.08% from the prior estimate of $94 ...

「Gタンパク質共役型受容体（GPCR）」は、がん性疼痛や気管支ぜんそくなど多くの疾患に関わるタンパク質です。これまでGPCRを標的に多くの薬が開発されてきましたが、最近、限界を迎え、従来の方法では活性の高い薬が見つかりにくくなっています。

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...